6-cyano-5-oxahexa-2-yne-1-ol | 802907-61-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 6-cyano-5-oxahexa-2-yne-1-ol
• 英文别名: 2-(4-hydroxybut-2-ynyloxy)acetonitrile；(4-hydroxy-but-2-ynyloxy)-acetonitrile；(4-Hydroxy-but-2-ynyloxy)-acetonitrile；2-(4-hydroxybut-2-ynoxy)acetonitrile
• CAS: 802907-61-5
• 化学式: C₆H₇NO₂
• 分子量: 125.127
• InChiKey: KSMJZAZCLNZPHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-cyano-5-oxahexa-2-yne-1-ol 在 Wilkinson's catalyst 、 偶氮二甲酸二异丙酯 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 氯苯 为溶剂， 反应 20.67h， 生成
  参考文献：
  名称：

  Dehydrogenative [2 + 2 + 2] Cycloaddition of Cyano-yne-allene Substrates: Convenient Access to 2,6-Naphthyridine Scaffolds

  摘要：

  A rhodium-catalyzed [2 + 2 + 2] cycloaddition of cyano-yne-allene scaffolds followed by a dehydrogenative process enabling the direct synthesis of unsaturated pyridine-containing compounds that can be conveniently converted to 2,6-naphthyridine derivatives is reported.

  DOI：

  10.1021/acs.orglett.5b01554
• 作为产物：
  描述：

  2-((4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-yn-1-yl)oxy)acetonitrile 在 甲醇 、 对甲苯磺酸 作用下， 以79%的产率得到6-cyano-5-oxahexa-2-yne-1-ol
  参考文献：
  名称：

  A [2 + 2 + 2]-Cycloaddition Approach toward 6-Oxa-allocolchicinoids with Apoptosis-Inducing Activity

  摘要：

  Following an A -> ABC strategy, a new synthesis of 6-oxa-allocolchicinoids was developed exploiting a microwave-promoted Co- or Rh-catalyzed intramolecular [2 + 2 + 2]-cycloaddition (alkyne cyclotrimerization) as a key step. The approach opens a short and efficient access to a variety of novel compounds, some of which were found to exhibit significant and selective apoptosis-inclucing activities against BJAB tumor cells.

  DOI：

  10.1021/ol802542c

文献信息

• Ruthenium-Catalyzed Cycloaddition of 1,6-Diynes and Nitriles under Mild Conditions: Role of the Coordinating Group of Nitriles
  作者：Yoshihiko Yamamoto、Keisuke Kinpara、Ryuji Ogawa、Hisao Nishiyama、Kenji Itoh

  DOI：10.1002/chem.200600176

  日期：2006.7.17

  to afford bicyclic pyridines. Careful screening of nitrile components revealed that a C[triple chemical bond]C triple bond or heteroatom substituents, such as methoxy and methylthio groups, proved to act as the coordinating groups, whereas C==C or C==O double bonds and amino groups failed to promote cycloaddition. This suggests that coordinating groups with multiple pi-bonds or lone pairs are essential

  在催化量的[Cp * RuCl（cod）]（Cp * =五甲基环戊二烯，cod = 1,5-环辛二烯）的存在下，使1,6-二炔与带有配位基团的腈发生化学和区域选择性反应在室温下，例如二氰化物或α-卤代腈，得到双环吡啶。仔细筛选腈成分显示，证明C [三化学键] C三键或杂原子取代基（例如甲氧基和甲硫基）充当配位基团，而C == C或C == O双键和氨基团体未能促进环加成反应。这表明具有多个π键或孤对的配位基团对于腈组分是必不可少的。
• Piperidinyl prostaglandin E analogs
  申请人：ALLERGAN, INC.

  公开号：US20040248854A1

  公开（公告）日：2004-12-09

  The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula I; 1 wherein X, Y, Z, D and R 3 are as defined in the specification. Also disclosed are compounds comprising 2 or a pharmaceutically acceptable salt or a prodrug thereof; wherein A, X, J, and R 3 are as defined in the specification. Also disclosed are compounds having an &agr; and an &ohgr; chain comprising 3 or derivatives thereof, as defined in the specification or pharmaceutically acceptable salts or prodrugs thereof.

  本发明提供了一种治疗眼压增高或青光眼的方法，包括向患有眼压增高或青光眼的动物施用一定剂量的通式I代表的化合物；其中X、Y、Z、D和R3如规范中定义。还披露了包括2或其药用盐或前药的化合物；其中A、X、J和R3如规范中定义。还披露了具有α和ω链的化合物，包括3或其衍生物，如规范中定义，或其药用盐或前药。
• Treatment of inflammatory bowel disease
  申请人：Old W. David

  公开号：US20050171062A1

  公开（公告）日：2005-08-04

  The present invention provides a method of treating inflammatory bowel disease which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound represented by the general formula 1; wherein X, Y, Z, D and R 3 are as defined in the specification. Also useful for the treatment of inflammatory bowel disease are compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein A, X, J, and R 3 are as defined in the specification. Also useful for the treatment of inflammatory bowel disease are compounds having an α and an ω chain comprising or derivatives thereof, as defined in the specification or pharmaceutically acceptable salts or prodrugs thereof.

  本发明提供了一种治疗炎症性肠病的方法，包括向患有眼压增高或青光眼的动物施用一定疗效的一般式1代表的化合物；其中X、Y、Z、D和R3如规范中所定义。还可用于治疗炎症性肠病的化合物包括或其药用盐或前药；其中A、X、J和R3如规范中所定义。还可用于治疗炎症性肠病的化合物包括具有α和ω链或其衍生物，如规范中所定义或其药用盐或前药。
• PIPERIDINYL PROSTAGLANDIN E ANALOGS
  申请人：ALLERGAN, INC.

  公开号：EP1631355A1

  公开（公告）日：2006-03-08
• TREATMENT OF INFLAMMATORY BOWEL DISEASE
  申请人：ALLERGAN, INC.

  公开号：EP1817033A1

  公开（公告）日：2007-08-15